• Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Paris
    MK3475-522 (Keynote-522)
    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    MARIE PAULE SABLIN

  • Paris
    DF6215-001
    A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

    EMANUELA ROMANO

  • Paris
    EUonQoL
    Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.

  • Paris
    GSK 219451 - POPSTAR
    Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).

    AMAURY LERUSTE

  • Paris, Saint-Cloud
    REVCCI
    Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia

    ABDELMALEK GHIMOUZ

  • Breast cancer
    Paris, Saint-Cloud
    HEROES
    De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

    DIANA BELLO ROUFAI

  • Paris, Saint-Cloud
    PEACE 7
    A randomised Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localised prostate cancer and high-risk features of relapse, from the Prostate Cancer Consortium in Europe (PEACE).

    GILLES CREHANGE, PIERRE GRAFF CAILLEAUD

  • Cervical cancer
    Saint-Cloud
    GYNET
    A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.

    DIANA BELLO ROUFAI

  • Lung cancer
    Paris
    HARMONi-3
    A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

    PAULINE DU RUSQUEC

  • Childhood and adolescent cancers
    Paris
    HR-NBL2
    High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

    GUDRUN SCHLEIERMACHER

  • Saint-Cloud
    IMMUNO-BIL (D48-1 PRODIGE 57)
    Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study

  • Thymic tumors
    Paris
    IMMUNO-TET
    Characterisation of the immune infiltrate and molecular features of Thymic Epithelial Tumours (TETs).

    CLEMENCE BASSE

  • Childhood and adolescent cancers
    Paris
    INFORM2 - NIVENT (IC 2018-07)
    INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies

    GUDRUN SCHLEIERMACHER

  • Thyroid cancer
    Saint-Cloud
    INTERMEDIATE-01
    Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy

    CAPUCINE RICHARD

  • Saint-Cloud
    IONESCO (IFCT-1601)
    A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer.

    MARIE ANGE MASSIANI

  • Saint-Cloud
    IROCAS - PRODIGE 52
    A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting

  • Paris
    LCB-1801-001
    A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS.

    EMANUELA ROMANO

  • Lung cancer
    Paris
    Lunar- 2
    LUNAR-2: a pivotal, randomized, open-label trial of Tumor Treating Fields (TTFields, 150 kHz) combined with pembrolizumab and platinum-based chemotherapy in the treatment of metastatic non·small cell lung cancer.

    NICOLAS GIRARD

  • Saint-Cloud
    M20-621
    A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    MAPAM-01
    Therapeutic Nipple Areola Skin-sparing Mastectomy.

    EUGENIE GUILLOT

  • Saint-Cloud
    MCLA-128-CL01
    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  • Saint-Cloud
    MCLA-128-CL02
    Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

    FRANCOIS-CLEMENT BIDARD

  • Paris
    MCLA-158-CL01
    Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Paris
    MCLA-158-CL02
    A phase 3, open-label, randomized, controlled study aimed at evaluating the efficacy and safety of petosemtamab compared to the investigator's choice of monotherapy in previously treated patients with metastatic/recurring, incurable head and neck squamous cell carcinoma

    CHRISTOPHE LE TOURNEAU

  • ENT/Head and Neck Cancers
    Paris
    MCLA-158-CL03/LiGeR-HN1
    A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

    CHRISTOPHE LE TOURNEAU

  • Thyroid cancer
    Saint-Cloud
    MIBI-THYR
    Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.

    CAPUCINE RICHARD

  • Saint-Cloud
    MIRASOL
    MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK 2140-010
    A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).

    CLEMENTINE SARKOZY

  • Lung cancer
    Paris
    MK-2870-004
    A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.

    CATHERINE DANIEL

  • Breast cancer
    Paris
    MK-2870-010
    An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

    DELPHINE LOIRAT